Welcome to our dedicated page for Lantern Pharma news (Ticker: LTRN), a resource for investors and traders seeking the latest updates and insights on Lantern Pharma stock.
Lantern Pharma Inc. (NASDAQ: LTRN) generates a steady flow of news as an AI-driven, clinical-stage oncology company advancing both a precision medicine pipeline and a proprietary artificial intelligence platform. News coverage on this page centers on developments in its RADR® AI and machine learning platform, clinical trial milestones for LP-184, LP-284, and LP-300, regulatory interactions, and strategic initiatives that shape the company’s position in AI-enabled cancer drug development.
Investors and researchers following LTRN news will find detailed updates on Phase 1 and Phase 2 clinical trials, including safety and efficacy readouts, biomarker findings, and disease control observations in heavily pre-treated cancer patients. Recent announcements have highlighted LP-184’s Phase 1a results in advanced solid tumors, LP-284’s activity in relapsed or refractory B-cell lymphomas, and LP-300 data from the HARMONIC™ trial in never-smoker non-small cell lung cancer. Lantern also reports on FDA designations such as Fast Track, Orphan Drug, and Rare Pediatric Disease status that influence development pathways for its drug candidates.
In addition to clinical results, Lantern’s news stream covers the evolution of its RADR® platform and related AI modules. Articles describe the launch and performance of tools like predictBBB.ai for blood–brain barrier prediction and LBx-AI for liquid biopsy-based treatment response modeling, as well as presentations at scientific meetings and symposia. Corporate news items include quarterly financial updates, at-the-market financing agreements, board appointments, proxy statements, and the announcement of an AI Center of Excellence in Bengaluru, India to scale RADR® and multi-agent AI systems for global biopharma partners.
By reviewing the LTRN news feed, readers can track how Lantern integrates AI, genomics, and clinical data into its oncology programs, how regulators and collaborators engage with its pipeline, and how the company positions its AI modules and partnerships in the broader biopharmaceutical landscape. This page is a resource for monitoring material events, clinical inflection points, and platform advances that Lantern discloses through press releases and regulatory communications.
Lantern Pharma (LTRN), a clinical-stage biopharmaceutical company, will hold a conference call on March 10, 2022, at 4:30 p.m. ET to discuss its fourth quarter and fiscal year 2021 financial results. Management, led by CEO Panna Sharma, will provide insights into the company's operating performance and guidance on upcoming milestones. Lantern Pharma specializes in oncology drug development leveraging its RADR® A.I. platform to enhance patient targeting for drug trials. The call will also be available via a replay on their investor relations website.
Lantern Pharma (NASDAQ: LTRN) announced a collaboration with The Greehey Children's Cancer Research Institute to expand its drug candidates, LP-184 and LP-284, into rare pediatric cancers. This partnership aims to validate findings from the RADR® platform and advance treatments for difficult-to-treat tumors like rhabdomyosarcoma and ATRT. The collaboration leverages GCCRI's expertise and models, seeking to accelerate pediatric cancer therapy development at reduced costs. Lantern has previously received FDA orphan drug designations for LP-184.
Lantern Pharma (LTRN) announced that the FDA granted Rare Pediatric Disease Designation and Orphan Drug Designation for its drug candidate LP-184, aimed at treating pediatric patients with ATRT (Atypical Teratoid Rhabdoid Tumor). LP-184 is also being investigated for genetically defined solid tumors like pancreatic cancer and GBM. The Rare Pediatric Disease designation may allow Lantern to receive a priority review voucher for future product applications. The firm focuses on using its RADR® A.I. platform to identify effective treatments tailored to patient genetics.
Lantern Pharma (NASDAQ: LTRN) announced a collaboration with The Danish Cancer Society Research Center to advance clinical development of its drug candidates, LP-100 and LP-184. This partnership aims to enhance diagnostic methods for identifying NER-deficient tumors. The collaboration will leverage Lantern's RADR® AI platform, potentially adding millions of data points and expediting cancer treatment discovery. Both LP-100 and LP-184 have shown promise in targeting NER deficiencies, with LP-100 currently in a phase 2 trial for metastatic prostate cancer, showing improved overall survival rates.
Lantern Pharma (LTRN) has expanded its collaboration with the National Cancer Institute (NCI) to enhance the development of its oncology drug candidates, LP-184 and LP-284. This partnership aims to leverage multiomic data to identify gene signatures predicting tumor responses. LP-184 is targeting pancreatic cancer and glioblastoma, while LP-284 focuses on leukemias and lymphomas. Initial results suggest LP-184 may be more effective in tumors resistant to current treatments. The partnership will continue to refine predictive biomarkers and advance clinical trials, with results expected to be published in peer-reviewed journals.
Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical company, announced its CEO Panna Sharma will present at the H.C. Wainwright BioConnect 2022 Conference from January 10-13, 2022. The presentation will be a fireside chat with analyst Michael King and will be available on-demand for attendees starting January 10 at 7:00 AM ET. Lantern Pharma utilizes its RADR® A.I. platform for oncology drug development, focusing on biomarker identification to enhance treatment outcomes for patients. More information can be found on their website.
On December 14, 2021, Lantern Pharma (NASDAQ: LTRN) announced positive data on LP-284's efficacy against hematologic cancers presented at the ASH Annual Meeting. LP-284, a synthetic acylfulvene compound, showcased broad anti-tumor activity against lymphoma, multiple myeloma, and leukemia in vitro. The findings suggest LP-284 could serve as a targeted therapy option for cancers with DNA repair deficiencies. Lantern plans to leverage its RADR® A.I. platform to advance LP-284 development and address the urgent need for new treatment options in blood cancers.
Lantern Pharma Inc. (NASDAQ: LTRN) has announced a share repurchase program to buy back up to $7 million of its common stock. This initiative aligns with the company's goal to enhance shareholder value and reflects confidence in its clinical pipeline and RADR® A.I. platform. As of September 30, 2021, Lantern held approximately $73.8 million in cash and marketable securities, with around 11.2 million shares outstanding as of October 29, 2021. The stock buyback will be executed based on market conditions and regulatory limitations.
Lantern Pharma (NASDAQ: LTRN) announced a virtual Key Opinion Leader (KOL) event on pancreatic cancer treatment featuring drug candidate LP-184. Scheduled for November 18, 2021, at 12:00 pm EST, the event will discuss LP-184's advances, a PTGR1-activated small molecule targeting genetically defined pancreatic cancer patients. Notable co-hosts include Dr. Igor Astsaturov, Dr. Ira Sharp, and Dr. Kishor G. Bhatia. Lantern's RADR® A.I. platform aims to transform oncology drug development. LP-184 has Orphan Drug Designation from the FDA for pancreatic cancer and glioblastoma.
Lantern Pharma (LTRN) announced its abstract on the efficacy of LP-184 in treating glioblastoma multiforme (GBM) has been accepted for virtual presentation at the Society for Neuro-Oncology 2021 Annual Meeting from November 18-21, 2021. The research indicates LP-184's effectiveness in both MGMT methylated and unmethylated GBM, particularly for those with DNA repair deficiencies. LP-184 has also received Orphan Drug Designation for malignant gliomas and pancreatic cancer. The findings support further development as a promising treatment for GBM.
FAQ
What is the current stock price of Lantern Pharma (LTRN)?
What is the market cap of Lantern Pharma (LTRN)?
